The US Food and Drug Administration (FDA) has cleared Wave Neuroscience’s precision neuromodulation platform for post-traumatic stress disorder (PTSD) treatment, providing a personalised, biomarker-guided clinical treatment for US patients with the disorder.

Wave’s magnetic electroencephalogram (EEG)-guided resonance therapy (MeRT) system analyses EEG-derived brain activity biomarkers with artificial intelligence (AI) to personalise the delivery of transcranial magnetic stimulation (TMS) therapy based on a patient’s unique neural activity patterns.

The California-based company asserts that MeRT’s personalised approach to the delivery of TMS deviates from the historical ‘one-size-fits-all’ approach to neuromodulation therapy for PTSD.